Anebulo Pharmaceuticals, Inc.
Other OTCTotal Valuation
Anebulo Pharmaceuticals, Inc. carries a market capitalization of 15.29M, placing it among publicly traded companies globally.
| Market Cap | 15.29M |
| Enterprise Value | N/A |
Share Statistics
Anebulo Pharmaceuticals, Inc. currently has 41.08M shares outstanding.
| Shares Outstanding | 41.08M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.53 |
| P/TBV Ratio | 5.23 |
| P/FCF Ratio | -7.11 |
| P/OCF Ratio | -7.11 |
Financial Position
Anebulo Pharmaceuticals, Inc. maintains a current ratio of 6.24, meaning it holds 6.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 6.24 |
| Quick Ratio | 6.12 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -27.23 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -63.16 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Anebulo Pharmaceuticals, Inc.'s stock has declined approximately -64.28571% over the past 52 weeks. The 50-day moving average sits at 0.57, while the 200-day moving average is 1.47.
| Beta (5Y) | N/A |
| 52-Week Price Change | -64.28571% |
| 50-Day Moving Average | 0.57 |
| 200-Day Moving Average | 1.47 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -8.10M, while operating income came in at -8.10M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -8.10M |
| Pretax Income | -7.98M |
| Net Income | -7.98M |
| EBITDA | -8.10M |
| EBIT | -8.10M |
| Earnings Per Share (EPS) | -0.19 |
Balance Sheet
Total book value stands at -78.01M, with working capital of 7.79M providing operational flexibility.
| Cash & Cash Equivalents | 9.04M |
| Total Debt | N/A |
| Net Debt | -9.04M |
| Equity (Book Value) | -78.01M |
| Book Value Per Share | -1.90 |
| Working Capital | 7.79M |
Cash Flow
Anebulo Pharmaceuticals, Inc. produced -5.84M in operating cash flow over the past twelve months.
| Operating Cash Flow | -5.84M |
| Capital Expenditures | N/A |
| Free Cash Flow | -5.84M |
| FCF Per Share | -0.14 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 0.28 |
| FCF Yield | -14.07 |
Scores
Anebulo Pharmaceuticals, Inc. posts an Altman Z-Score of 3.32, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.32 |